Updating results

59 results for psoriasis

Sort: Relevance | Date

Psoriasis

All NICE products on psoriasis. Includes any guidance, NICE Pathways and quality standards.

Topic page

Psoriasis: assessment and management (CG153)

This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

Clinical guideline Published October 2012 Last updated September 2017

Psoriasis

Everything NICE has said on psoriasis in an interactive flowchart

NICE Pathway Published October 2011 Last updated August 2019

Psoriasis (QS40)

This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.

Quality standard Published August 2013

Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults

Technology appraisal guidance Published July 2006

Adalimumab for the treatment of adults with psoriasis (TA146)

Evidence-based recommendations on adalimumab (Humira) for the treatment of adults with plaque psoriasis

Technology appraisal guidance Published June 2008

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018

Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults

Technology appraisal guidance Published September 2009 Last updated March 2017

Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2019

Secukinumab for treating moderate to severe plaque psoriasis (TA350)

Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

Technology appraisal guidance Published July 2015

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published August 2019

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2019

Guselkumab for treating moderate to severe plaque psoriasis (TA521)

Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published June 2018

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2017

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people

Technology appraisal guidance Published July 2017

Spondyloarthritis in over 16s: diagnosis and management (NG65)

This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

NICE guideline Published February 2017 Last updated June 2017

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Evidence-based recommendations on etanercept (Enbrel) infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis

Technology appraisal guidance Published August 2010

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published October 2018

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published May 2017

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published August 2018

Spondyloarthritis

Everything NICE has said on diagnosing and managing spondyloarthritis in people aged 16 and over in an interactive flowchart

NICE Pathway Published February 2017 Last updated March 2019

Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]

Proposed [GID-TA10554] Expected publication date: TBC

Technology appraisal guidance Proposed

Grenz rays therapy for inflammatory skin conditions (IPG236)

Evidence-based recommendations on Grenz rays therapy for treating inflammatory skin conditions (including eczema and psoriasis)

Interventional procedures guidance Published November 2007

Golimumab for the treatment of psoriatic arthritis (TA220)

Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis

Technology appraisal guidance Published April 2011

Spondyloarthritis (QS170)

This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

Quality standard Published June 2018

Ustekinumab for treating active psoriatic arthritis (TA340)

Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults

Technology appraisal guidance Published June 2015 Last updated March 2017

Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional

Technology appraisal guidance Published September 2016

Block scoping reports

This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.

Published July 2019 Last updated July 2019

Changes we're making to health technology evaluation

Involved in NICE executive group Myeloma UK NET Patient Foundation Psoriasis and Psoriatic Arthritis Alliance The methods working group

Published December 2019 Last updated December 2019

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults

Technology appraisal guidance Published August 2009

Self-management:- Do structured psoriasis-focused self-management programmes improve patient confidence, wellbeing and disease control compared with standard care?

Recommendation ID CG153/4 Question Self-management:- Do structured psoriasis-focused self-management programmes improve patient...

Research recommendation Published June 2015

Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility...

Research recommendation Published October 2018

Past appeals and decisions

treatment of malignant pleural mesothelioma (2) 23 November 2007 TA103 Psoriasis - efalizumab and etanercept 27 January 2006 TA104...

Published May 2019 Last updated May 2019

Musculoskeletal conditions

Everything NICE has said on musculoskeletal conditions in an interactive flowchart

NICE Pathway Published December 2013 Last updated October 2019

Static list

NICE technology appraisal guidance static list

Published January 2018 Last updated January 2018

What are the costs associated with best supportive care?

from guidance Tildrakizumab for treating moderate to severe plaque psoriasis Number TA575 Date issued April 2019 Other details

Research recommendation Published August 2019

What are the cost associated with best supportive care?

guidance Certolizumab pegol for treating moderate to severe plaque psoriasis Number TA574 Date issued April 2019 Other details

Research recommendation Published August 2019

Psoriasis - briakinumab (suspended) [ID65]

In development [GID-TAG412] Expected publication date: TBC

Technology appraisal guidance In development

Atopic eczema in under 12s (QS44)

This quality standard covers diagnosing and managing atopic eczema in children under 12. It describes high-quality care in priority areas for improvement.

Quality standard Published September 2013

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Technology appraisal guidance Published February 2016

Pulmonary sarcoidosis: infliximab (ES2)

Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published December 2016

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

Technology appraisal guidance Published December 2015

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017